Title:Immunotherapy in Combination with Chemotherapy for Triple-negative
Breast Cancer
Volume: 24
Issue: 4
Author(s): Melendez Solano Elizabeth, Stevens Barrón Jazmín Cristina and Chapa González Christian*
Affiliation:
- Grupo de Investigación Nanomedicina, Instituto de Ingeniería y Tecnología, Universidad Autónoma de Ciudad Juárez,
Ciudad Juárez, Chihuahua, 32310, México
Keywords:
Cancer, breast, triple-negative breast cancer, immunotherapy, efficacy, safety, atezolizumab, camrelizumab, paclitaxel, gemcitabine.
Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks
estrogen and progesterone receptors and does not overexpress the human epidermal growth factor receptor
2 (HER2). Previous treatment options for TNBC were limited to chemotherapy alone, resulting
in a poor patient prognosis. In 2018, an estimated 2.1 million new cases of breast cancer were diagnosed
globally, with the incidence increasing by 0.5% annually from 2014 to 2018. The exact prevalence
of TNBC is difficult to determine because it is based on the absence of certain receptors and
overexpression of HER2. Treatment options for TNBC include surgery, chemotherapy, radiation therapy,
and targeted therapy. The available evidence suggests that combination immunotherapy using
PD-1/PD-L1 inhibitors may be a promising treatment option for metastatic TNBC. In this review, we
evaluated the efficacy and safety of different immunotherapies regimens for the treatment of TNBC.
In many clinical trials, the overall response rate and survival were better in patients treated with these
drug combinations than those treated with chemotherapy alone. Although definitive treatments are not
within reach, efforts to gain a deeper understanding of combination immunotherapy have the potential
to overcome the urge for safe and effective treatments.
